MBCC

New breast cancer subtype proves challenging to define molecularly, pathologically, clinically

More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge

Honing indications for de-escalation of treatment intensity and, yes, selective omission of RT

Established role in metastatic disease, may eventually replace chemotherapy

Physician laments decline in research quality, critical appraisal during pandemic

Also: Combination targets uncommon form of advanced HER2-mutant disease

Moving beyond chemotherapy to immunotherapy, PARP inhibitors, ADCs, combinations

Ongoing trials could help some women avoid even less-invasive sentinel lymph node biopsy

New therapies breach blood-brain barrier to improve response, survival

Defining high risk, considering role of Ki-67, BRCA mutations

Switching drugs, taking aim at different targets under investigation